Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



From the monthly archives: May 2021

We are pleased to present below all posts archived in 'May 2021'. If you still can't find what you are looking for, try using the search box.

University of Birmingham Enterprise: Agents that target viral RNA could be the basis for next generation broad spectrum anti-viral drugs– new study

A new approach to tackling viruses by targeting the ‘control centre’ in viral RNA could lead to broad spectrum anti-viral drugs and provide a first line of defence against future pandemics, according to new research at the University of Birmingham.

Read the rest of entry »

The Oxford Science Park: Magdalen College seeks Strategic Partner to accelerate development of The Oxford Science Park

Oxford, UK, May 10 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, has announced1 that it is seeking a strategic partner with which to accelerate development of the Park.

Read the rest of entry »

Inivata to be Acquired by NeoGenomics

Research Triangle Park, NC, USA and Cambridge, UK, 5 May 2021 -- Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO.), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has agreed to acquire Inivata. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million.  

Read the rest of entry »

The Electrospinning Company: Company raises £4.5m ($6.3m) with participation from new strategic investor

Company raises £4.5m ($6.3m) with participation from new strategic investor

Proceeds to be used to expand electrospinning capabilities & capacity, driving company growth

 Harwell, UK, May 4 2021 – The Electrospinning Company (Electrospinning), a leader in the development and manufacture of nanofibrous biomaterials for use in tissue regenerative devices, has completed a £4.5m ($6.3m) fundraising round, led by US materials science company Confluent Medical Technologies Inc. (Confluent) as a strategic investor. New investor Intuitive Investments Group plc also participated, alongside existing investors Downing Ventures, the Science and Technology Facilities Council and individual business angels. The proceeds of the fundraising round will be used to enhance the company’s capability and capacity through semi-automation, enhanced materials processing and quality systems.

 

Read the rest of entry »

Midlands investment opportunities revealed in report from Midlands Innovation universities

5 May, 2021:  Midlands Innovation Universities are set to reveal opportunities for investment in the region that have been identified in a report produced by Beauhurst, a platform that provides data on the UK's high-growth and innovative companies, at an event on Thursday 12th May.

Read the rest of entry »

RSSL Wins Business of the Year Award

Reading Scientific Services Ltd (RSSL) has been named Business of the Year 2021 at the Thames Valley Awards, with the judges praising its forward-thinking approach and strong commercial performance.

Read the rest of entry »

Discovery Park: Collaboration will connect capabilities in the life sciences sector

A partnership between the National Horizons Centre and Discovery Park, the Life Sciences Opportunity Zone for ambitious companies, is promising to bring opportunities to both organisations.

Read the rest of entry »

Enesi Pharma’s ImplaVax®-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

OXFORD, UK – 6 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical swine fever (CSF) vaccine.

Read the rest of entry »

Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

OXFORD, UK – 5 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. The project, which started in October 2019, received funding from the Bill & Melinda Gates Foundation.

Read the rest of entry »

Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax® technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.